Germany Intravenous Immunoglobulin Market Size & Outlook
Germany intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Germany intravenous immunoglobulin market highlights
- The Germany intravenous immunoglobulin market generated a revenue of USD 745.7 million in 2024 and is expected to reach USD 1,063.6 million by 2030.
- The Germany market is expected to grow at a CAGR of 6.1% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Intravenous immunoglobulin market data book summary
| Market revenue in 2024 | USD 745.7 million |
| Market revenue in 2030 | USD 1,063.6 million |
| Growth rate | 6.1% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, Germany accounted for 5.4% of the global intravenous immunoglobulin market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany intravenous immunoglobulin market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 952.0 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 20.77% in 2024. Horizon Databook has segmented the Germany intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is witnessing steady growth in the IVIG market, primarily due to an increasing focus on treating immunodeficiency diseases and related conditions like ITP and Multifocal Motor Neuropathy. Hospital and specialty pharmacies are the primary points of distribution, with increasing partnerships between healthcare providers and major suppliers like Octapharma AG and Grifols SA. These companies are working to meet the growing demand for IVIG therapies and expand their reach in the German market.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany intravenous immunoglobulin market size, by application, 2018-2030 (US$M)
Germany Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
